Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies

BACKGROUND: Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2. METHODS: ATC were generated from PBMC activated for 14 days with anti-CD3 mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Zitron, Ian M, Thakur, Archana, Norkina, Oxana, Barger, Geoffrey R, Lum, Lawrence G, Mittal, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599512/
https://www.ncbi.nlm.nih.gov/pubmed/23433400
http://dx.doi.org/10.1186/1471-2407-13-83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599512/
https://www.ncbi.nlm.nih.gov/pubmed/23433400
http://dx.doi.org/10.1186/1471-2407-13-83

Ejemplares similares